




RealRate

PHARMACEUTICAL 2017

Albireo Pharma INC
Rank 110 of 308



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Albireo Pharma INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Albireo Pharma INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 49% points. The greatest weakness of Albireo Pharma INC is the variable Liabilities, Current, reducing the Economic Capital Ratio by 24% points.

The company's Economic Capital Ratio, given in the ranking table, is 307%, being 62% points above the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	30,861
Cost of Goods Sold	0
Intangible Assets	18,260
Liabilities, Current	12,708
Liabilities, Non-Current	0
Other Assets	518
Other Compr. Net Income	692
Other Expenses	-143
Other Liabilities	0
Other Net Income	-3,994
Other Revenues	11,364
Property and Equipment	21
Research and Development	8,077
Selling, General and Administrative Expense	15,786

Output Variable	Value in 1000 USD
Assets	49,660
Liabilities	12,708
Expenses	23,720
Revenues	11,364
Stockholders Equity	36,952
Net Income	-16,350
Comprehensive Net Income	-16,004
BaseVar	51,069
ECR before LimitedLiability	207%
Economic Capital Ratio	307%